Metsera enters merger agreement with Pfizer

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

Pfizer Sweetens Its Offer for Metsera in Bidding War Against Novo

Metsera enters merger agreement with Pfizer

Metsera , an obesity drug developer, said on Friday that it has entered into an amended merger agreement with Pfizer , in which the New York-based company will acquire Metsera for up to $86.25 per share.

Metsera says Pfizer to buy Metsera for up to $86.25 per share

Metsera Inc: Pfizer and Metsera enter into merger agreement amendment; Metsera's board of directors reaffirms support of merger with Pfizer Metsera Inc - revised deal values Metsera at up to...

Pfizer to acquire Metsera for $47.50/share in $4.9 billion deal

Pfizer nears $7.3B acquisition of Metsera, boosting weight-loss drug portfolio.